Add-on aliskiren treatment can decrease blood pressure but requires attention to risks of renal impairment and hyperkalemia Chikushi Anti-Hypertension Trial-Rasilez® (CHAT-Ras)

References

• Ad-hoc working group of E, Fliser D, Laville M, Covic A, Fouque D, Vanholder R, Juillard L, Van Biesen W. A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant. 2012;27:4263–72. doi:10.1093/ndt/gfs375
   PubMed Web of Science ®Google Scholar
• Alderman MH, Ooi WL, Cohen H, Madhavan S, Sealey JE, Laragh JH. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am J Hypertens. 1997;10:1–8. doi:10.1016/S0895-7061(96)00301-9.
   PubMed Web of Science ®Google Scholar
• Rouleau J-L, Packer M, Moye L, de Champlain J, Bichet D, Klein M, Rouleau JR, Sussex B, Arnold JM, Sestier F, et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol. 1994;24:583–91.
   PubMed Web of Science ®Google Scholar
• Wood JM, Maibaum J, Rahuel J, Grutter MG, Cohen N-C, Rasetti V, Rüger H, Göschke R, Stutz S, Fuhrer W, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun. 2003;308:698–705.
   PubMed Web of Science ®Google Scholar
• Fisher NDL, Jan Danser AH, Nussberger J, Dole WP, Hollenberg NK, Dole WP, Hollenberg NK. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation. 2008;117:3199–205. doi:10.1161/CIRCULATIONAHA.108.767202.
   PubMed Web of Science ®Google Scholar
• Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ito S, Iwao H, et al. The Japanese society of hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res. 2009;32:3–107.
   PubMed Web of Science ®Google Scholar
• Parving -H-H, Brenner BM, McMurray JJV, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204–13.
   PubMed Web of Science ®Google Scholar
• Kushiro T, Itakura H, Abo Y, Gotou H, Terao S, Keefe DL. Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res. 2006;29:997–1005. doi:10.1291/hypres.29.997.
   PubMed Web of Science ®Google Scholar
• Kushiro T, Itakura H, Abo Y, Gotou H, Terao S, Keefe DL. Long-term safety, tolerability, and antihypertensive efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertension. Hypertens Res. 2009;32:169–75. doi:10.1038/hr.2008.21.
   PubMed Web of Science ®Google Scholar
• Howard JP, Francis DP. Overcoming the three biases obscuring the science of renal denervation in humans: big-day bias, check-once-more bias and I-will-take-it-now bias. Trends Cardiovasc Med. 2015;25:116–18. doi:10.1016/j.tcm.2014.10.011.
   PubMed Web of Science ®Google Scholar
• Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007;370:221–29. doi:10.1016/S0140-6736(07)61124-6.
   PubMed Web of Science ®Google Scholar
• Chrysant SG, Murray AV, Hoppe UC, Dattani D, Patel S, Hsu H, Zhang J. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis. Curr Med Res Opin. 2008;24:1039–47.
   PubMed Web of Science ®Google Scholar
• Brown MJ, McInnes GT, Papst CC, Zhang J, MacDonald TM. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet. 2011;377:312–20. doi:10.1016/S0140-6736(10)62003-X.
   PubMed Web of Science ®Google Scholar
• Liu Y, Yan R, Song A, Niu X, Cao C, Wei J, Dong X, Gao D. Aliskiren/amlodipine vs. aliskiren/hydrochlorothiazide in hypertension: indirect meta-analysis of trials comparing the two combinations vs. monotherapy. Am J Hypertens. 2014;27:268–78.
   PubMed Web of Science ®Google Scholar
• Choi DE, Jeong JY, Lim BJ, Chang Y-K, Na K-R, Shin Y-T, Lee KW. Aliskiren ameliorates renal inflammation and fibrosis induced by unilateral ureteral obstruction in mice. J Urol. 2011;186:694–701.
   PubMed Web of Science ®Google Scholar
• Sun CY, Cherng WJ, Jian HZ, Hsu HH, Wu IW, Hsu HJ. Aliskiren reduced renal fibrosis in mice with chronic ischemic kidney injury–beyond the direct renin inhibition. Hypertens Res. 2012;35:304–11.
   PubMed Web of Science ®Google Scholar
• Sakuraya K, Endo A, Someya T, Hirano D, Murano Y, Fujinaga S, Ohtomo Y, Shimizu T. The synergistic effect of mizoribine and a direct renin inhibitor, aliskiren, on unilateral ureteral obstruction induced renal fibrosis in rats. J Urol. 2014;191:1139–46.
   PubMed Web of Science ®Google Scholar
• Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK, Investigators AS. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433–46. doi:10.1056/NEJMoa0708379.
   PubMed Web of Science ®Google Scholar
• Ito S, Nakura N, Le Breton S, Keefe D. Efficacy and safety of aliskiren in Japanese hypertensive patients with renal dysfunction. Hypertens Res. 2010;33:62–66. doi:10.1038/hr.2009.175.
   PubMed Web of Science ®Google Scholar
• Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Parving HH. Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy. Clin J Am Soc Nephrol. 2011;6:1025–31. doi:10.2215/CJN.07590810.
   PubMed Web of Science ®Google Scholar
• Persson F, Rossing P, Reinhard H, Juhl T, Stehouwer CD, Schalkwijk C, Danser AHJ, Boomsma F, Frandsen E, Parving -H-H, et al. Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial. Diabetologia. 2010;53:1576–80.
   PubMed Web of Science ®Google Scholar
• Matavelli LC, Huang J, Siragy HM. Combined aliskiren and amlodipine reduce albuminuria via reduction in renal inflammation in diabetic rats. J Cardiovasc Pharmacol. 2012;59:281–87. doi:10.1097/FJC.0b013e31823fc3f5.
   PubMed Web of Science ®Google Scholar
• Persson F, Rossing P, Schjoedt KJ, Juhl T, Tarnow L, Stehouwer CD, Schalkwijk C, Boomsma F, Frandsen E, Parving -H-H, et al. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int. 2008;73:1419–25.
   PubMed Web of Science ®Google Scholar
• Kelly DJ, Zhang Y, Moe G, Naik G, Gilbert RE. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia. 2007;50:2398–404. doi:10.1007/s00125-007-0795-9.
   PubMed Web of Science ®Google Scholar
• Tang SC, Lin M, Tam S, Au WS, Ma MK, Yap DY, Ho YW, Lai KN. Aliskiren combined with losartan in immunoglobulin A nephropathy: an open-labeled pilot study. Nephrol Dial Transplant. 2012;27:613–18.
   PubMed Web of Science ®Google Scholar
• Moriyama T, Tsuruta Y, Kojima C, Itabashi M, Sugiura H, Takei T, Ogawa T, Uchida K, Tsuchiya K, Nitta K, et al. Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease. Int Urol Nephrol. 2012;44:841–45.
   PubMed Web of Science ®Google Scholar
• Riccioni G. Blood pressure control and favourable pleiotropic effects of aliskiren. Hypertens Res. 2013;36:102–03. doi:10.1038/hr.2012.202.
   PubMed Web of Science ®Google Scholar